Magnetic resonance (MR)
contrast agents focusing on special functions are required to improve
cancer diagnosis, particularly in the early stages. Here, we designed multifunctional solid
lipid nanoparticles (SLNs) with simultaneous loading of
gadolinium (Gd) diethylenetriaminepentaacetic
acid (
Gd-DTPA) and
octadecylamine fluorescein isothiocyanate (
FITC) to obtain Gd-
FITC-SLNs as a
tumor-absorbable nanoparticle
contrast agent for the histological confirmation of MR imaging (MRI) findings.
Colorectal tumors were evaluated in vitro and in vivo via direct uptake of this
contrast agent, which displayed reasonable T1 relaxivity and no significant cytotoxicity at the experimental concentrations in human colon
carcinoma cells (HT29) and mouse colon
carcinoma cells (CT26). In vitro cell uptake experiments demonstrated that
contrast agent absorption by the two types of
cancer cells was concentration-dependent in the safe concentration range. During in vivo MRI, transrectal infusion of Gd-
FITC-SLNs showed more significant enhancement at the
tumor site compared with the infusion of
Gd-DTPA in female C57/BL mice with
azoxymethane/
dextran sulfate sodium-induced colorectal highgrade intraepithelial
neoplasia. Subsequent confocal fluorescence microscopy demonstrated Gd-
FITC-SLNs as highly concentrated green fluorescent spots distributed from the
tumor capsule into the
tumor. This study establishes the "proof-of-principle" of a new MRI technique wherein
colorectal tumors are enhanced via direct absorption or uptake of the nanoparticle
contrast agent.